WallStSmart

Palo Alto Networks Inc (PANW)vsCommScope Holding Company, Inc. (VISN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Palo Alto Networks Inc generates 391% more annual revenue ($9.89B vs $2.02B). VISN leads profitability with a 347.7% profit margin vs 13.0%. VISN appears more attractively valued with a PEG of 2.94. VISN earns a higher WallStSmart Score of 74/100 (B).

PANW

Buy

57

out of 100

Grade: C

Growth: 8.0Profit: 6.0Value: 4.7Quality: 4.5
Piotroski: 1/9Altman Z: 1.02

VISN

Strong Buy

74

out of 100

Grade: B

Growth: 6.7Profit: 6.5Value: 5.0Quality: 7.0
Piotroski: 5/9Altman Z: 0.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

PANWUndervalued (+39.7%)

Margin of Safety

+39.7%

Fair Value

$441.96

Current Price

$272.05

$169.91 discount

UndervaluedFair: $441.96Overvalued

Intrinsic value data unavailable for VISN.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

PANW3 strengths · Avg: 10.0/10
Market CapQuality
$241.01B10/10

Mega-cap, among the largest globally

EPS GrowthGrowth
60.5%10/10

Earnings expanding 60.5% YoY

Debt/EquityHealth
0.0710/10

Conservative balance sheet, low leverage

VISN6 strengths · Avg: 9.3/10
Price/BookValuation
0.6x10/10

Reasonable price relative to book value

Profit MarginProfitability
347.7%10/10

Keeps 348 of every $100 in revenue as profit

EPS GrowthGrowth
704.0%10/10

Earnings expanding 704.0% YoY

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

P/E RatioValuation
17.3x8/10

Attractively priced relative to earnings

Revenue GrowthGrowth
21.6%8/10

Revenue surging 21.6% year-over-year

Areas to Watch

PANW4 concerns · Avg: 2.5/10
Return on EquityProfitability
3.0%3/10

ROE of 3.0% — below average capital efficiency

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

PEG RatioValuation
5.042/10

Expensive relative to growth rate

P/E RatioValuation
256.2x2/10

Premium valuation, high expectations priced in

VISN3 concerns · Avg: 2.0/10
PEG RatioValuation
2.942/10

Expensive relative to growth rate

Free Cash FlowQuality
$-228.80M2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
0.342/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : PANW

The strongest argument for PANW centers on Market Cap, EPS Growth, Debt/Equity. Revenue growth of 14.9% demonstrates continued momentum.

Bull Case : VISN

The strongest argument for VISN centers on Price/Book, Profit Margin, EPS Growth. Profitability is solid with margins at 347.7% and operating margin at 7.1%. Revenue growth of 21.6% demonstrates continued momentum.

Bear Case : PANW

The primary concerns for PANW are Return on Equity, Piotroski F-Score, PEG Ratio. A P/E of 256.2x leaves little room for execution misses.

Bear Case : VISN

The primary concerns for VISN are PEG Ratio, Free Cash Flow, Altman Z-Score.

Key Dynamics to Monitor

PANW profiles as a value stock while VISN is a growth play — different risk/reward profiles.

VISN carries more volatility with a beta of 1.93 — expect wider price swings.

VISN is growing revenue faster at 21.6% — sustainability is the question.

PANW generates stronger free cash flow (788M), providing more financial flexibility.

Bottom Line

VISN scores higher overall (74/100 vs 57/100), backed by strong 347.7% margins and 21.6% revenue growth. PANW offers better value entry with a 39.7% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Palo Alto Networks Inc

TECHNOLOGY · SOFTWARE - INFRASTRUCTURE · USA

Palo Alto Networks, Inc. provides cybersecurity platform solutions globally. The company is headquartered in Santa Clara, California.

CommScope Holding Company, Inc.

TECHNOLOGY · COMMUNICATION EQUIPMENT · USA

Gyroscope Therapeutics Holdings plc, a clinical-stage gene therapy company, develops gene therapy products to treat patients with eye diseases. The company is headquartered in Stevenage, the United Kingdom.

Want to dig deeper into these stocks?